^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AGO2 overexpression

    i
    Other names: AGO2, Argonaute RISC Catalytic Component 2, Cancer Susceptibility Candidate 7 (Non-Protein Coding) 2, Eukaryotic Translation Initiation Factor 2C 2, PAZ Piwi Domain Protein, Protein Argonaute-2, Protein Slicer, LINC00980, EIF2C2, PPD, Q10, Eukaryotic Translation Initiation Factor 2C, Long Intergenic Non-Protein Coding RNA 980, Argonaute 2 RISC Catalytic Component, Cancer Susceptibility Candidate 7, Argonaute 2, Argonaute2, EIF-2C 2, EIF2C 2, CASC7, HAGO2, HAgo2
    Entrez ID:
    27161
    11ms
    Plasma extracellular vesicles-AGO2-related microRNAs as potential prognosis biomarkers in clear-cell renal cell carcinoma (EACR 2023)
    The low secretion of EVs-derived miR-132 could lead to a microenvironment where oncogenic functions associated with AGO2 overexpression is potentiated. Larger clinical setting validation studies are needed in order to validate the potential application of miR-132 as ccRCC biomarker.
    AGO2 (Argonaute RISC Catalytic Component 2) • MIR132 (MicroRNA 132) • MIR15 (MicroRNA 15) • MIR15B (MicroRNA 15b)
    |
    AGO2 overexpression
    1year
    CircAGO2 promotes colorectal cancer progression by inhibiting heat shock protein family B (small) member 8 via miR-1-3p/retinoblastoma binding protein 4 axis. (PubMed, Funct Integr Genomics)
    RBBP4 silencing decreased RBBP4 expression and reduced proliferation and invasion of cells where circAGO2 and miR-1-3p were silenced. CircAGO2 overexpression decoyed miR-1-3p to increase RBBP4 expression, which inhibited HSPB8 transcription via histone deacetylation in HSPB8 promoter region, promoting proliferation and invasion of CRC cells.
    Journal
    |
    AGO2 (Argonaute RISC Catalytic Component 2)
    |
    AGO2 overexpression
    over1year
    Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma. (PubMed, PLoS One)
    Moreover, the analytic results using a publicly available NCBI GEO dataset revealed that AGO2 overexpression was associated with shorter overall survival among patients with MM (p = 0.032, HR = 1.60, 95% CI, 1.04 to 2.46). In conclusion, MTA2 and AGO2 proteins were first identified as potential biomarkers that reflect disease activity, provide prognostic values and could serve as non-invasive indicators for disease monitoring and outcome predicting among patients with MM.
    Journal • Adverse events
    |
    MTA2 (Metastasis Associated 1 Family Member 2) • AGO2 (Argonaute RISC Catalytic Component 2)
    |
    AGO2 overexpression